The Food and Drug Administration announced Thursday that it is investigating certain powdered infant formula following four customer reports of children contracting serious infections.
, the FDA said infections stemming from the bacterium Cronobacter sakazakii and the strain Salmonella Newport have been linked to powdered infant formula produced in Abbott Nutrition’s Sturgis, Michigan, facility.
Consumers are advised to avoid certain powdered infant formula products that come from that location while the administration works with the Centers for Disease Control and Prevention, as well as state and local partners, to examine the reports. If parents or caregivers notice that an infant has those symptoms or has recently consumed those products, the FDA encourages them to contact a health care provider and get medical care immediately., Abbott Nutrition issued a voluntary recall for the affected products and said its testing showed that no distributed product has tested positive for the presence of either bacterium.
Dr. Kate Lockwood, a pediatrician at Children’s Hospital of Philadelphia, previously spoke to "TODAY" about tips parents and caregivers can use to feed their children.
Norge Siste Nytt, Norge Overskrifter
Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.
At Good Pierogi, it's all about 'food that supports drinking'At Krem Miskevich's Polish pop-up, eating and drinking are not separate acts.
Les mer »
Will the Future of Food Be a World Without Meat?What if meat-eating became a thing of the past? A new book explores the impact that widespread veganism could have on society.
Les mer »
At the ultimate Super Bowl party, nearly 2,000 pounds of food are saved from the dumpsterOn Super Bowl Sunday, the Food Recovery Network delivered surplus food from the Players Tailgate party.
Les mer »
What Makes Oaxacan Food Oaxacan?The influences, ingredients, and essential dishes you need to know to understand Oaxacan cuisine
Les mer »
Reckitt baby food is problem child best kept homeOffloading the sluggish Enfamil unit would boost the Nurofen maker’s growth. But rivals Nestlé or Abbott would face regulatory hurdles, while a buyout group would probably pay less than the unit’s 5.4 bln pound book value. CEO Laxman Narasimhan is better off holding on.
Les mer »